Welcome to Argonaut Therapeutics

Argonaut is developing novel epigenetic therapies targeting arginine methylation in cancer.

Group

Argonaut Therapeutics

Is a precision therapeutics company that was established to develop epigenetically-acting drugs which target abnormal arginine methylation in cancer. The company was founded on pioneering research from the University of Oxford, UK. Argonaut Therapeutics strives to develop a new class of precision cancer medicines which target the enzymes responsible for abnormal arginine methylation in cancer.

Our Mission

Argonaut’s Therapeutics' mission is to deliver hope to cancer patients through new drugs targeting arginine methylation.

News

Argonaut Therapeutics Announces Successful Completion of Financing Round

Oxford, UK, March 2019 – Argonaut Therapeutics, a leading developer of novel cancer therapies, announced…

Read More...

Argonaut Therapeutics Announces Appointment of New Board Director Nick Dixon-Clegg OSI

Oxford, UK, 1 August 2020 – Argonaut Therapeutics, a leading developer of novel cancer agents,…

Read More...

Argonaut Therapeutics Announces Appointment of New Board Director Dr Chan Hee Park of JW Pharmaceutical Corporation

Oxford, UK, 21 January 2021 – Argonaut Therapeutics, a leading developer of novel cancer agents,…

Read More...

Investors

small logo-3
Read more
small logo-2
Read more
small logo-1
Read more

Partners

Department of Oncology Logo
Read more
Target Discovery Institute Logo
Read more
o2h (high res logo)small
Read more